8-K: STRATA Skin Sciences Reports Modest Revenue Growth and Improved Profitability in Q1 2025

STRATA Skin Sciences announces a 1% revenue increase and significant gross margin expansion in the first quarter of 2025, alongside a corporate update.

Summary

• STRATA Skin Sciences reported its financial results for the first quarter ended March 31, 2025.
• Revenue increased by 1% to $6.8 million compared to the same period in 2024.
• Global net recurring XTRAC revenue was $4.5 million, a slight decrease from $4.6 million in the prior year, but international growth offset a domestic decline.
• The average net revenue per domestic XTRAC system increased by 3% year-over-year to $4,776.
• Equipment revenue rose by 1.4% to $2.1 million.
• Gross margin significantly improved to 53.5%, up from 45.6% in the prior year.
• Operating expenses decreased by 5% to $5.7 million.
• The company's operating cash flow improved by $254,000 to negative $550,000.
• Adjusted EBITDA improved by $732,000 to negative $547,000.
• The company's cash balance at the end of the quarter was $7.8 million.
• The net loss for the quarter was $2.4 million, or negative $0.58 EPS, compared to a net loss of $3.4 million, or negative $0.96 EPS, in the first quarter of 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to improved gross margins and cost control, despite the continued net loss. The company is making progress, but still has work to do to achieve profitability.

Positives

• Revenue saw a modest increase of 1% year-over-year.
• Gross margins expanded significantly, nearly 800 basis points year-over-year.
• Operating expenses were reduced by 5% year-over-year.
• Adjusted EBITDA improved by $732,000 year-over-year.
• The direct-to-consumer strategy is showing positive results with increased patient engagement.
• International market growth is strong, contributing a significant portion of total revenue.

Negatives

• Global net recurring XTRAC revenue decreased slightly.
• The company still reported a net loss of $2.4 million for the quarter.
• Operating cash flow remains negative at $550,000.

Risks

• The company faces risks related to financial, economic, business, competitive, market, and regulatory factors.
• Adverse market conditions, labor supply shortages, or supply chain interruptions could impact results.
• International conflicts and political factors could affect the company's performance.
• Global tariff uncertainty could impact international growth.

Future Outlook

The company anticipates continued growth in international markets once global tariff uncertainty clears, adding strong growth to U.S. business stabilization and growth.

Management Comments

• STRATA made solid progress in the first quarter in executing our strategic plan, said Dr. Dolev Rafaeli, STRATA President and CEO.
• Along with a modest increase in revenue, we have significantly improved our gross margins, expanding nearly 800 basis points year over year.
• We have also maintained disciplined cost control resulting in a decline in operating expenses and improvement in our seasonally low first quarter adjusted EBITDA.
• Our existing direct-to-consumer (DTC) strategy continues to strengthen, driving 32% and 128% more unique Psoriasis and Acne patients respectively, as compared to prior year period demonstrating both growing demand and improved marketing efficiency.
• Internationally, were building strong momentum.
• Revenue from international markets grew 8% in Q1 as compared to prior year, following 41% growth in the previous quarter.
• This segment now accounts for 36% of our total revenue, and we anticipate, once the global tariff uncertainty clears it will continue to grow, adding strong growth to our U.S. business stabilization and growth, concluded Dr. Rafaeli.

Industry Context

The company operates in the medical technology sector, focusing on dermatology and aesthetics. The results reflect a focus on profitability and international expansion, which are common strategies in this industry.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing the specific competitors STRATA Skin Sciences benchmarks against.
• However, companies like Cynosure, Cutera, and Lumenis are key players in the aesthetic laser and energy-based device market.
• A gross margin of 53.5% is generally competitive within the medical device industry, but specific comparisons would require a deeper dive into peer performance.
• The focus on recurring revenue through the XTRAC system is a common strategy to build a stable revenue base, similar to business models employed by companies offering consumables or subscription services.

Stakeholder Impact

• Shareholders may view the improved gross margins and cost control positively.
• Employees may be affected by the cost control measures.
• Customers may benefit from the company's focus on innovative products.
• Suppliers may be impacted by the company's financial performance.

Key Dates

Keywords

STRATA Skin Sciences, Financial Results, Q1 2025, XTRAC, Dermatology, EBITDA, Revenue, Gross Margin